FDA Expands Use of Approved Breast Cancer Drug : RushPRNews - Newswire & Global Press Release Distribution

 
Bookmark and Share

FDA Expands Use of Approved Breast Cancer Drug

February 1, 2010

Washington D.C. (RPRN) 02/01/10 — Provides oral regime for hormone positive and HER2-positive advanced breast cancer

The U.S. Food and Drug Administration today approved Tykerb (lapatinib) in combination with Femara (letrozole) to treat hormone positive and HER2-positive advanced breast cancer in postmenopausal women for whom hormonal therapy is indicated.

HER2 is a protein involved in normal cell growth. It is found on some types of cancer cells, including breast cancer cells. In hormone positive breast cancer, the presence of certain hormones contributes to breast cancer growth. In HER2-positive breast cancer, stimulation of the HER2 receptor contributes to cancer cell growth. Breast cancer is the second leading cause of death among women. More than 192,000 women will be diagnosed with breast cancer this year.

“This drug combination of Tykerb plus Femara provides women being treated for advanced breast cancer with an important treatment option. This entirely oral treatment regimen works by targeting both HER2 and the hormone receptors, thereby slowing the cancer cells’ ability to grow or spread,” said Richard Pazdur, M.D., director of the Office of Oncology Drug Products, in the FDA’s Center for Drug Evaluation and Research.

Women with HER2-positive disease receiving the Tykerb plus Femara combination more than doubled the time they lived without the cancer progressing compared with those receiving Femara alone (35 weeks vs. 13 weeks). Women in the company sponsored study were randomized to receive Tykerb plus Femara or Femara alone. It is too early to determine whether an improvement in overall survival will be observed in the clinical trial.

Tykerb works by depriving tumor cells of signals needed to grow. Tykerb enters the cell and blocks the function of the HER2 protein.

Tykerb was initially approved in combination with a chemotherapy drug, Xeloda (capecitabine) in 2007. This combination was used to treat women with advanced breast cancer tumors with the HER2 protein who had received prior treatment with chemotherapy drugs, including an anthracycline and a taxane, and Herceptin (trastuzumab), an anti-cancer antibody used to treat HER2-positive advanced breast cancer.

Safety information from this study was consistent with previous Tykerb clinical studies in advanced breast cancer. The most commonly reported side effects of the combination were diarrhea, rash, nausea and fatigue. Treatment with Tykerb also has been associated with decreases in heart function, liver damage, and lung tissue inflammation. Fetal harm may occur if used to treat advanced breast cancer in pregnant women. Patients should talk to their health care provider about the potential side effects, drug interactions, and other medical conditions.

 

Tykerb is marketed by Collegeville, Pa.-based GlaxoSmithKline.
Femara is marketed by Lebanon, Pa.-based Novartis AG.

 

For more information:

 

FDA Office of Oncology Drug Products
http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm091745.htm

 

National Cancer Institute – Breast Cancer
http://www.cancer.gov/cancertopics/types/breast

 

RSS Feed for FDA News Releases [what is RSS?]

About the author:

FDA is an agency within the Department of Health and Human Services and consists of seven centers and offices

Click here to see all news from this author/company

Filed Under: FDA- Pharmaceutical news, Health and Fitness, Food-Nutrition, Lifestyle, PRESS RELEASE

RUSH PR NEWS newswire and press release services at rushprnews.com / Anne Howard annehowardpublicist.com

Content- Legal Responsibility - All material is copyrighted - You may repost but you MUST link back to the original post on your page and acknowledge Rush PR News as the news source. Rush PR News is not legally and/or morally responsible for content of press releases, opinions expressed or fact-checking.

Rush PR News cannot be held legally responsible for material published and distributed through its newswire service or published in its press-room and therefore cannot be sued for published material. Third-party must be contacted directly to dispute content.

Rush PR News is not the contact for material published.

RSSFeed PRESS & SOCIAL MEDIA RELEASES

Newborn Foundation Featured on Global Health Panel at Annual Patient Safety Science and Technology Summit

SAINT PAUL, MN and IRVINE, CA-- 01/23/15 ·  - The Newborn Foundation, an international nonprofit leveraging medical...

Cape Coral Waterfront Estate Known as “The UPS House” to be Sold at February 10th Absolute Auction

Fort Myers, Florida 01/21/15 · Truck Driver Turned Executive Selling Florida Riverfront Dream...

Studio One selects Visual 2000 End2End Suite of Fashion Business Solutions

LONDON, UK 01/20/15 · Visual 2000 International announces manufacturer Studio One  are...

CPD Seminar: How Skill Trade Workers Will be Effected by Express Entry

Vancouver, BC - 01/19/15 · Ashton College Announces Seminar Addressing Express Entry - New...

Dr. Ken Pool, IT Pioneer, dead at 62, leaves a rich legacy in health data standards and public health

ARLINGTON, TX 01/17/15 · With deep sadness  OZ Systems announces the sudden passing...

Dr. Ken Pool, Founder and Chairman of Dallas-based OZ Systems, Dies at 62

ARLINGTON, TX 01/16/15 · It is with deep sadness that OZ Systems announces...

Real Estate Auction – Is It Right for You?

Charlotte, NC 01/12/15 · Luxury homeowners looking to sell their estates face...

Philippines to Host Largest Crowd in Human History

Manila, Philippines 01/12/15 · The largest gathering of humans ever recorded will...

First Dedicated Canadian Bitcoin Price Index Launched

Vancouver, BC 01/08/15 · The Canadian Bitcoin Index (CBIX) created by Vancouver...

OnServe & Learning Brick has expanded to Niagara/Southwestern ON.

Kingston, ON 01/06/15 · Onserve is your trusted IT services company in...

Music Host Network Wants Writers Now!

LOS ANGELES 01/06/15 · The Music Host Network, a music media site...

Identify genuine web traffic from bots and botnets

SAN FRANCISCO 01/06/15 · As a provider of high-quality web traffic, Traffic...

Author Manfred Popp publishes - You can do what I did: lose weight, improve your health, stay fit -

Gaimersheim / Germany 01/06/15 · New book from author Manfred Popp about Weight...